3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
3
Neoplasms
2
Hematologic Neoplasms
2
HER2-positive Breast Cancer
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Lymphoproliferative Disorders
1
Lung Neoplasms
1
Gallbladder Neoplasms
1
Colorectal Neoplasms
1
Interventions
Oxaliplatin
15
Fluorouracil
13
Bevacizumab
13
Leucovorin
10
Capecitabine
8
Folfox protocol
7
Irinotecan
6
IFL protocol
4
Cetuximab
4
Folic Acid
3
Aspirin
3
atezolizumab
2
XELOX
2
Surgical Procedures, Operative
2
Magnetic Resonance Spectroscopy
2
Drug Therapy
2
Chemotherapy, Adjuvant
2
trifluridine tipiracil drug combination
1
trametinib
1
titanium silicide
1
sulindac sulfone
1
spartalizumab
1
sacituzumab govitecan
1
regorafenib
1
raltitrexed
1
pertuzumab
1
irinotecan sucrosofate
1
folfirinox
1
envafolimab
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Colorectal Neoplasms
×
pertuzumab
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled